E3 PreliminaryPreliminaryPEM not requiredReview-NarrativePeer-reviewedReviewed
Standard · 3 min
Glial Activation and Expression of the Serotonin Transporter in Chronic Fatigue Syndrome.
Noda, Mami, Ifuku, Masataka, Hossain, Md Shamim et al. · Frontiers in psychiatry · 2018 · DOI
Quick Summary
This review examines how brain inflammation might cause ME/CFS symptoms. When the body fights off a viral infection, special immune cells in the brain called microglia and astrocytes can become overactive and trigger a chain of events that reduces serotonin levels—a chemical important for mood and energy. Understanding this pathway could help researchers develop new treatments for ME/CFS.
Why It Matters
This research provides a testable molecular framework for how infection or immune activation could trigger and maintain ME/CFS symptoms. Identifying specific pathways like serotonin dysregulation offers concrete targets for future drug development, potentially offering new treatment options for ME/CFS patients who currently lack effective therapies.
Observed Findings
Infection with viral mimetics triggers sequential activation of microglia and astrocytes in the brain
This immune activation leads to increased blood-brain barrier permeability
Astrocyte activation results in upregulation of the serotonin transporter (5-HTT)
Reduced serotonin availability decreases activation of the 5-HT1A receptor subtype
Inferred Conclusions
Neuroinflammation driven by microglia and astrocyte activation may be a central mechanism in immunologically-induced ME/CFS
Dysregulation of serotonin signaling through increased 5-HTT expression represents a plausible link between immune activation and ME/CFS symptoms
Therapeutic targeting of TLR3 signaling, IL-1β production, or serotonin transporter function may offer new treatment strategies for ME/CFS
Remaining Questions
Do these neuroinflammatory mechanisms actually occur in human ME/CFS patients, and can they be directly measured in clinical studies?
Which triggers (viral infections, other pathogens, non-infectious stressors) initiate this cascade in susceptible individuals?
What This Study Does Not Prove
This review does not provide direct human evidence that these mechanisms actually occur in ME/CFS patients—it synthesizes animal and cellular models. It does not prove that all cases of ME/CFS involve viral triggers or these specific immune pathways. The model describes association and proposed mechanisms, not definitive causation in human disease.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Contribute
Private, reviewed by a human. Not a public comment thread.
Are there genetic or immunological factors that determine whether an individual develops ME/CFS after immune activation?
Would therapeutic interventions targeting these pathways (e.g., TLR3 antagonists, IL-1β blockers, serotonin transporter modulators) be safe and effective in ME/CFS clinical trials?